The Russian Direct Investment Fund (RDIF) has reported that the Sputnik V vaccine demonstrated a 97.2% efficacy against Covid-19 during the vaccination campaign in Belarus.
Based on an established and well-studied platform of human adenoviral vectors, Sputnik V leverages heterogeneous boosting which uses two separate vectors for two shots.
This boosting approach offers immunity for an extended duration than vaccines that use the same delivery mechanism for both vaccines.
The efficacy of the vaccine was assessed based on data from more than 860,000 individuals inoculated between January and July this year.
The latest real-world data of the Ministry of Health of the Republic of Belarus showed that Sputnik V was demonstrated to have increased efficacy and a greater safety profile against Covid-19.
Furthermore, no severe adverse events or deaths linked to the vaccine were reported, RDIF noted.
In December 2020, Belarus became the first outside Russia to register Sputnik V and use it for inoculation of the population.
RDIF and partners enabled the technology transfer to localise the manufacture of Sputnik V by Belarus-based company Belmedpreparaty, which is currently producing the vaccine.
In April 2021, Sputnik V produced in Belarus was authorised by the country’s Ministry of Health.
Russia’s single-dose Sputnik Light vaccine was registered in Belarus during the same month.
Sputnik Light contains the first component of Sputnik V and is based on human adenovirus serotype 26.
The Gamaleya National Research Center of Epidemiology and Microbiology and the RDIF reported that Sputnik V showed a 97.6% efficacy.
This was based on the analysis of data on the disease infection rate among people receiving both shots of the vaccine.